Pramipexole/rasagiline - Pharma Two B
Alternative Names: P2B-001; Rasagaline/pramipexoleLatest Information Update: 11 Dec 2024
At a glance
- Originator Pharma Two B
- Class Amines; Antidepressants; Antiparkinsonians; Benzothiazoles; Indans; Small molecules
- Mechanism of Action Dopamine D2 receptor agonists; Dopamine D3 receptor agonists; Monoamine oxidase B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Parkinson's disease
Most Recent Events
- 05 Dec 2024 Pooled efficacy data from a phase II and phase III trial in Parkinson’s Disease released by Pharma Two B
- 13 Apr 2024 Pooled adverse events data from a phase II and phase III trial in Parkinson’s Disease presented at the 76th Annual Meeting of the American Academy of Neurology 2024 (AAN-2024)
- 14 Nov 2023 Updated adverse events data from a phase III trial in Parkinson's-disease released by Pharma Two B